{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Thrombocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Mucocitis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Acute Kidney Injury"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Atrial Fibrilation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hypercalcemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hyponatremia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hypotension"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Lymph Node Pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Rash"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Respiratory Failure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Supraventricular Tachycardia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Thromboembolic Event"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"To assess the safety and tolerability of MLN9708, the number of patients experiencing Adverse Events (AEs) greater than or equal to grade 3 will be recorded.","groups":[{"description":"MLN9708 4mg by mouth weekly (days 1, 8, 15) every 28 days.\n\nMLN9708","id":"OG000","title":"MLN9708"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"30 days after the last dose of study drug","title":"Number Patients That Experience Adverse Events, Grades 3-5","type":"SECONDARY","unitOfMeasure":"participants"}